Combination of sacral neuromodulation and tolterodine for treatment of idiopathic
overactive bladder in women: a clinical trial.
Author(s): Tang H(1), Chen J(2), Wang Y(2), Yu T(2), Guo C(2), Liao X(2).
Affiliation(s): Author information:
(1)Department of Urinary Surgery, The Second Hospital of Sanming, Yong'an,
366000, Fujian Province, China. tanghuaBM@163.com. (2)Department of Urinary
Surgery, The Second Hospital of Sanming, Yong'an, 366000, Fujian Province, China.
Publication date & source: 2014, Urol J. , 11(4):1800-5
PURPOSE: To evaluate the efficacy of intermittent percutaneous needle sacral
nerve stimulation (IPN-SNS) in women with idiopathic overactive bladder (IOAB)
treated with tolterodine.
MATERIALS AND METHODS: A total of 240 female patients diagnosed with IOAB were
randomized to receive tolterodine only treatment (group 1, n = 120) or
tolterodine combined with IPN-SNS (group 2, n = 120). Each group included 120
participants, who were divided into subgroups depending on whether they had dry
OAB (urinary frequency and urgency) or wet OAB (urinary frequency and urgency
with urgency incontinence). In the treatment group, patients received
percutaneous IPN-SNS plus tolterodine (2 mg once daily), while in the control
group, only tolterodine (2 mg once daily) was administered for 3 months. The
voiding diary and urodynamic parameters were monitored, and patients'
psychological depression and anxiety scores were recorded before and after
treatment.
RESULTS: There were significantly greater improvements in the conditions of first
desire to void (FDV), maximum cystometric capacity (MCC), and daily average
volumes, as well as the daily single maximum voided volumes in group 2 (P = .001)
than in group 1. In addition, there were significantly greater decreases in
self-rating depression scale (SDS) and self-rating anxiety scale (SAS) scores in
group 2 compared with group 1 (P < .001).
CONCLUSION: Combined treatment with tolterodine plus IPN-SNS can not only improve
the symptoms of voiding dysfunction but can also reduce the concomitant
depression and anxiety in women with IOAB, thereby improving patients' quality
of life.
|